Cabozantinib for the treatment of solid tumors: a systematic review

Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin and Daniel Castellano

Abstract

Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence and the real-world performance of cabozantinib compared with clinical trial data, we performed a systematic review of cabozantinib monotherapy as treatment for solid tumors in adults.

Methods: This study was designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and registered with PROSPERO (CRD42020144680). We searched for clinical and observational studies of cabozantinib monotherapy for solid tumors using Embase, MEDLINE, and Cochrane databases (October 2020), and screened relevant congress abstracts. Eligible studies reported clinical or safety outcomes, or biomarker data. Small studies (n < 25) and studies of cabozantinib combination therapies were excluded. Quality was assessed using National Institute for Health and Care Excellence methodology, and study characteristics were described qualitatively.

Results: Of 2888 citations, 114 were included (52 randomized studies, 29 observational studies, 32 nonrandomized phase I or II studies or pilot trials, and 1 analysis of data from a randomized study and a nonrandomized study). Beyond approved indications, other tumors studied were castration-resistant prostate cancer, urothelial carcinoma, Ewing sarcoma, osteosarcoma, uveal melanoma, non-small-cell lung cancer, Merkel cell carcinoma, glioblastoma, neuroendocrine tumors, and breast, endometrial and ovarian cancers. The most common adverse events were hypertension, diarrhea, and fatigue.

Conclusion: The identified evidence demonstrates the positive efficacy/effectiveness of cabozantinib monotherapy in various solid tumor types, with safety findings being consistent with those observed with other VEGFR-targeting tyrosine kinase inhibitors. When available, real-world findings were consistent with the data reported from clinical trials. A limitation of this review is the high proportion of abstracts; however, this allowed us to capture the most up-to-date findings.

Keywords: cabozantinib, hepatocellular carcinoma, renal cell carcinoma, solid tumor, tyrosine kinase inhibitor, vascular endothelial growth factor

Introduction

Vascular endothelial growth factor (VEGF) receptor and hepatocyte growth factor receptor (MET) are involved in signaling pathways that regulate angiogenesis, epithelial to mesenchymal transition, cell proliferation, and cell migration.1 Overexpression of VEGF receptor and MET promotes tumor growth and metastasis.1 The kinase...
AXL is also linked to tumor pathogenesis, signaling to promote metastasis. As well as promoting tumor growth, dysregulation of VEGF, MET, and AXL signaling pathways is also associated with immune suppression, leading to inhibition of antitumor immunity. Cabozantinib is the only approved tyrosine kinase inhibitor (TKI) that targets VEGF receptors (VEGFRs), MET, and AXL.

Cabozantinib is approved for several indications both in the Europe and in the United States. In Europe, cabozantinib monotherapy is approved for the treatment of the following patients: adult patients with advanced renal cell carcinoma (RCC) who are naive to treatment and have intermediate or poor risk in terms of prognosis [tablets, 60 mg once daily (QD)];

adults with advanced RCC who have received prior VEGF-targeted therapy (tablets, 60 mg QD);

adults with progressive, unresectable locally advanced or metastatic medullary thyroid cancer (MTC; capsules, 140 mg QD); and adults with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib (tablets, 60 mg QD). In Europe, the Committee for Medicinal Products for Human Use endorsed the use of cabozantinib in differentiated thyroid cancer (DTC), based on the results of the COSMIC-311 study; a decision from the European Commission is awaited, at the time of writing. In the United States, cabozantinib monotherapy is approved for the treatment of patients with advanced RCC (tablets, 60 mg QD);

patients with progressive, metastatic MTC (capsules, 140 mg QD); and patients with HCC who have previously been treated with sorafenib (tablets, 60 mg QD) and adult and pediatric patients (aged 12 years and older) with locally advanced or metastatic DTC that has progressed following prior VEGF-targeted therapy and who are radioiodine refractory, or ineligible (tablets, 60 mg QD). These approvals were based on the following: a randomized phase III study demonstrated improved objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) in patients with advanced RCC compared with everolimus; a phase III trial comparing cabozantinib with placebo showed improved ORR, PFS, and OS in patients with advanced progressive HCC; and a phase III trial comparing cabozantinib with placebo showed improved PFS in progressive MTC. It should be noted that cabozantinib capsules and tablets are not bioequivalent and cannot be used interchangeably.

Cabozantinib is also approved in combination with nivolumab for the first-line treatment of adults with advanced RCC in the European Union and in the United States. Cabozantinib has also been investigated for the treatment of other types of solid tumors. For example, the use of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) has been investigated in two phase III randomized controlled trials (RCTs; COMET-1 and COMET-2), and has recently been assessed in DTC in a phase III RCT (COSMIC-311). With evidence growing in multiple disease areas, there is a need to establish an up-to-date understanding of the use of cabozantinib in the treatment of solid tumors, focusing on the clinical efficacy, comparative effectiveness, and safety profile of cabozantinib as a monotherapy for solid tumors. To address these needs, we performed a systematic literature review (SLR) to identify the clinical and observational data on cabozantinib monotherapy for the treatment of different types of solid tumor in adults and to understand how the real-world performance of cabozantinib monotherapy compares with the data reported in pivotal clinical trials. As a secondary aim of this SLR, we also assessed which biomarkers are being explored to guide treatment decisions relating to the use of cabozantinib monotherapy. Although associations between biomarkers and patient response to cancer therapy have huge potential in guiding treatment decisions, a thorough evaluation of this broad topic was beyond the scope of this review.

Materials and methods

Search strategy

The protocol for this SLR was registered with the International Prospective Register of Systematic Reviews (PROSPERO; registration name: ‘A systematic literature review of cabozantinib for the treatment of solid tumors’; registration number: CRD42020144680). Published studies of cabozantinib as a monotherapy for solid tumors were identified through a systematic search. MEDLINE In-Process & Other Non-Indexed Citations and Ovid MEDLINE (1946–present), Embase (1974–present), and the Cochrane Library were searched on 9 October 2020 (see Supplemental Resource 1 for search terms used in Embase).
**Supplementary searches**

Congress abstracts were searched from 1 January 2016 to 9 October 2020. The congresses included were as follows: American Society of Clinical Oncology (ASCO), ASCO Gastrointestinal Cancers Symposium, ASCO Genitourinary Cancers Symposium, European Society for Medical Oncology, and American Association for Cancer Research. The bibliographies of studies identified in the electronic searches were reviewed to identify the additional relevant references.

**Study selection and data collection**

Citations identified by the searches were screened against prespecified criteria in accordance with the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. During screening, abstracts and titles were reviewed by a single reviewer against the eligibility criteria and uncertainties were resolved by a second reviewer. Eligibility criteria are presented in Table 1. During data extraction, study population data and key results relating to efficacy, safety and biomarkers were extracted manually for each included study.

**Quality assessment**

Quality was assessed using National Institute for Health and Care Excellence methodology checklists. Studies were given a rating according to their level of potential bias in terms of internal and external validity. All studies are included in the Results section, regardless of their quality rating.

**Results**

**Overview of evidence**

*Results of SLR.* In total, 2888 citations were identified by the electronic searches after de-duplication; of these, 386 proceeded to full paper review. A further 20 articles were considered relevant for full-text review, including 17 from congress searches and 3 from bibliographies of studies identified in the electronic searches. Following full paper review, 292 articles were excluded, of which 77 were excluded according to *post hoc* exclusion criteria, including RCTs and real-world studies with a sample size of fewer than 25; biomarker studies carried out in cell lines; *in vitro* cultures or *in vivo* models; encores of abstracts already included; or abstracts that had been superseded by articles that were included. The final number of studies included in this review was 114 (Figure 1).

*Characteristics of included studies.* Of the 114 included articles, 106 reported efficacy, effectiveness, and/or safety outcomes; of these, 47 reported findings from RCTs or randomized discontinuation trials (RDTs), 28 reported findings from observational or retrospective studies, and 31 reported findings from nonrandomized phase I or II studies (Supplemental Resource 2). Among the identified RCTs and RDTs, cabozantinib was evaluated versus placebo or versus the active comparators everolimus, temozolomide, dacarbazine, mitoxantrone, prednisone, or sunitinib. The most commonly studied disease type in terms of efficacy was RCC (Figure 2). Among the included studies, 54 articles contained data on biomarkers.

In terms of quality assessment, 21/114 studies had the highest rating for internal validity. Poorer ratings were predominantly due to a lack of study details reported in congress abstracts (58 were abstracts, and 35 were articles).

**Efficacy and effectiveness of cabozantinib monotherapy**

*Renal cell carcinoma. Evidence from randomized studies.* Two RCTs evaluated cabozantinib in patients with RCC: the phase III METEOR trial and the phase II CABOSUN trial. The METEOR trial compared cabozantinib 60 mg ($n = 330$) with everolimus 10 mg ($n = 328$) QD in patients who received prior treatment with at least one VEGFR-targeting TKI; approximately 70% of patients received study treatment as a second-line therapy. Results demonstrated a superior efficacy for cabozantinib in all three endpoints: PFS (primary endpoint, with 90% statistical power), and OS and ORR (secondary endpoints). The disease control rate [DCR; defined as complete response (CR) + partial response (PR) + stable disease (SD)] was 83% in the cabozantinib group and 66% in the everolimus group. Subgroup analyses of patients in this study with or without prior nephrectomy showed cabozantinib improved PFS, ORR, and OS compared with everolimus in patients with advanced RCC, irrespective of nephrectomy status. Similarly, a retrospective analysis of patients in the METEOR trial stratified by age group (<65, 65–74, and ⩾75 years) reported improved PFS,
ORR, and OS compared with everolimus, irrespective of age group. A post hoc pooled analysis of patients from METEOR and a Japanese, open-label, phase II study showed similar efficacy results, irrespective of prior treatment with immuno-oncology agents.

The CABOSUN trial compared cabozantinib 60 mg (n = 79), as a first-line therapy in patients at intermediate and poor risk only, with sunitinib 50 mg (n = 78). Patients receiving cabozantinib had a significantly lower risk of progression (primary endpoint, with 85% statistical power) than those receiving sunitinib (p = 0.0008). Risk of death was not significantly different between treatment groups; however, the study was not powered for survival differences. The DCRs for cabozantinib and sunitinib were 75% and 47%, respectively. Characteristics and key findings from these studies are presented in Table 2.

Evidence from real-world studies: In all, 21 publications relating to 16 retrospective or observational analyses investigated OS, PFS, or response (primary endpoints were not specified) of cabozantinib (60 mg or not reported) in RCC (Figure 3). Of the 16 studies, 13 were in patients with advanced or metastatic RCC in which the histological subtypes were either mixed or not reported. Two studies evaluated patients with advanced or metastatic non-clear-cell RCC, and one study was conducted in patients with metastatic clear-cell RCC. Effectiveness data reported in real-world studies were broadly similar to the efficacy data reported in the RCTs (Figure 3). OS was reported in 12 publications.
relating to 11 studies and ranged from 9.1 to 25.4 months. PFS was reported in 10 studies and ranged from 5.6 to 12.5 months. The ORR (or the proportion of patients with CR + PR) was reported in 13 publications relating to 12 studies and ranged from 14% to 52%. The DCR or clinical benefit rate (or proportion of CR + PR + SD) was reported by 12 publications relating to 11 studies and ranged from 50% to 96%. The time to treatment failure was reported in four studies and ranged from 5.7 to 7.4 months.

Subgroup analyses of a UK study (CERES) of 100 patients with advanced RCC reported found that patients who were enrolled early in the study had similar outcomes to those that who enrolled later, but lower (≤6 versus >6) Charlson Comorbidity Index scores were associated with longer OS and PFS. In a US-based retrospective study (n = 65), increased body mass index

---

Figure 1. PRISMA diagram of included and excluded studies in the SLR. ITC, indirect treatment comparison; MA, meta-analysis; NMA, network meta-analysis; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomized controlled trial; SLR, systematic literature review.
6 weeks after initiation of cabozantinib therapy was significantly associated with prolonged OS [hazard ratio (HR) 0.90; 95% confidence interval (CI): 0.83–0.98; \( p = 0.016 \)].\(^5\) The CABOREAL study investigated the real-world use of cabozantinib in the French Early Access Program.\(^4\),\(^9\),\(^5\) A subgroup analysis of patients enrolled in CABOREAL by age showed similar clinical outcomes regardless of age; median (95% CI) OS was 13.6 (10.2–15.4) months for patients younger than 65 years, 16.2 (14.1–19.5) months for those aged 65–75 years and 13.3 (6.5–18.3) months for aged 75 years and older.\(^4\) A post hoc analysis in 47 patients with non-clear-cell RCC enrolled in CABOREAL by subtype showed that cabozantinib is particularly effective in papillary RCC type 1, with median OS of 16 months.\(^5\) Two abstracts relating to the same French retrospective single-center study based on the Institut Gustave Roussy RCC database were included,\(^4\),\(^1\) the second with an additional eight patients.\(^2\) This later abstract reported that ORR was higher in patients who had received prior immune checkpoint blockade (ICB; 49%; 54% clear-cell RCC versus 17% non-clear-cell RCC) than in those who had received prior TKI (21%; 27% clear-cell RCC versus 14% non-clear-cell RCC).\(^2\) Finally, another retrospective analysis, using a multinational database, investigated the effectiveness of cabozantinib in patients with metastatic RCC. Median (95% CI) OS was 30.7 (15.8–36.8), 17.8 (11.9–23.3), 12.6 (9.3–21.7) and 14.9 (10.2–21.7) months in the first-, second-, third- and fourth-line settings, respectively. ORR was maintained over the different lines of treatment, at 32% in the first line, 26% in the second line, 51% in the third line, and 29% in the fourth line.\(^5\)

**Evidence from nonrandomized phase I and II clinical studies:** In phase I study, patients \((n = 25)\) who received prior therapies (median: two) received cabozantinib (capsule, 140 mg QD). Median OS and PFS were 15.0 months and 12.9 months, respectively. Numbers of patients with PR, SD, and PD were 7 (28%), 13 (52%), and 1 (4%), respectively.\(^5\) A phase II, open-label, single-arm study of cabozantinib (60 mg QD) in Japanese patients \((n = 35)\) with advanced RCC who had received at least one prior TKI (one prior TKI: 70%; two prior TKIs: 23%; three or more prior TKIs: 9%) reported an ORR of 20%, a clinical benefit rate (CR + PR + SD) of 86% and a 6-month PFS estimate of 72.3% [median PFS and OS were not reached (NR)].\(^5\) 

**Hepatocellular carcinoma. Evidence from randomized studies:** One phase III RCT (CELESTIAL trial) compared cabozantinib 60 mg \((n = 470)\) with placebo \((n = 237)\) in patients with HCC who had been treated with sorafenib and had received up to
Table 2. Summary of clinical efficacy and safety findings from key randomized controlled trials of cabozantinib.

| Trial name (and reference of primary publication) | Tumor type and patient population | Line of therapy or patient treatment history | Treatment comparison and doses | Details of statistical power | Findings for primary endpoint(s) | Findings for secondary endpoint(s) | Safety data for cabozantinib arm |
|--------------------------------------------------|---------------------------------|---------------------------------------------|-------------------------------|-----------------------------|---------------------------------|---------------------------------|---------------------------------|
| METEOR[13]                                       | aRCC or mRCC Patients were ≥18 years of age with a clear-cell component and measurable disease | Patients must have received prior treatment with one or more VEGFR TKI and must have had radiographic progression during treatment or in the 6 months after the most recent dose of the VEGFR inhibitor. There was no limit to the number of previous anticancer therapies | Cabozantinib (n = 330) versus everolimus (n = 328) Cabozantinib 60 mg orally QD; everolimus 10 mg orally QD | Primary endpoint: under assumption of 259 events (disease progression or death), there was 90% power to detect an HR of 0.667 (cabozantinib versus everolimus), using the log-rank test and a two-sided significance level of 0.05. Observed number of events was 247. Secondary endpoint: under assumption of 408 deaths, there was 80% power to detect an HR of 0.75 (cabozantinib versus everolimus), using the log-rank test and a two-sided significance level of 0.04. Observed number of deaths was 320[21] | PFS: Median 7.4 [95% CI: 5.6–9.1] months for cabozantinib HR at first analysis (first 375 patients who underwent randomization), 0.58 [95% CI: 0.45–0.75; p < 0.0001].[13] Follow-up was at least 11 months. HR for all randomized patients, 0.51 [95% CI: 0.41–0.62; p < 0.0001].[21] Median follow-up was 18.7 months in the cabozantinib arm and 18.8 months in the everolimus arm | OS: Unadjusted HR at first interim analysis, 0.67 [95% CI: 0.51–0.89; p = 0.005].[13] Follow-up was at least 6 months. HR at second interim analysis, 0.66 [95% CI: 0.53–0.83; p < 0.001]. Follow-up 21.4 months in the cabozantinib arm and 16.5 months in the everolimus arm. Additional analysis with extended follow-up: HR, 0.70 [95% CI: 0.58–0.85; p = 0.002]. Median follow-up was 28 months | 331 patients [100%] had at least one AE [any grade] 226 patients [68%] had grade 3–4 AEs 31 patients [9%] discontinued treatment 197 patients [60%] had a dose reduction. Most common grade 3–4 AEs were: hypertension, 49 [15%]; diarrhea, 38 [11%]; fatigue, 30 [9%]; PPES, 28 [8%] |

Continued
| Trial name (and reference of primary publication) | Tumor type and patient population | Line of therapy or patient treatment history | Treatment comparison and doses | Details of statistical power | Findings for primary endpoint(s) | Findings for secondary endpoint(s) | Safety data for cabozantinib arm |
|--------------------------------------------------|----------------------------------|---------------------------------------------|-------------------------------|-------------------------------|----------------------------------|----------------------------------|----------------------------------|
| CABOSUN\(^a\)                                    | aRCC or mRCC Patients were ≥18 years of age with a clear-cell component and measurable disease, and must have been classified as intermediate or poor risk by IMDC criteria | First line | Cabozantinib \(n = 79\) versus sunitinib \(n = 78\) Cabozantinib 60mg orally QD; sunitinib 50mg orally QD for 4 weeks, followed by a 2-week break | Under assumption of 123 events [progressions or deaths], there was 85% power to detect an HR of 0.67 for PFS, using the log-rank test and a one-sided type I error of 0.12. The required number of events [123] was reached | PFS [progression or death]: Adjusted HR, 0.66 [95% CI: 0.46–0.95; \(p = 0.012\); adjusted by stratification factors [IMDC risk groups and presence or absence of bone metastases]].[^10] Median follow-up was 21.4 months Additional analysis of PFS when PFS was assessed by an investigator/independent radiology review committee. Median follow-up was 25.0 months[^11] Assessed by investigator, median [95% CI] PFS was 8.3 [6.5–12.4] months for cabozantinib and 5.4 [limit not reported accurately] months for sunitinib [HR, 0.56 [95% CI: 0.37–0.83]; \(p = 0.0042\)];[^12] Assessed by an independent radiology review committee, median [95% CI] PFS was 8.6 [6.8–14.0] months for cabozantinib and 5.3 [3.0–8.2] months for sunitinib [HR, 0.48 [95% CI: 0.31–0.74]; \(p < 0.001\)][^13] | OS: Original analysis [median follow-up, 21.4 months]: median [95% CI] OS was 30.3 [14.6–35.0] months for cabozantinib and 21.8 [16.3–27.0] months for sunitinib [adjusted HR 0.80 [95% CI: 0.50–1.28]; \(p =\text{not reported}\)][^14] Updated analysis [median follow-up, 35.4 months]: median [95% CI] OS was 26.1 [14.6, upper limit not estimable] months for cabozantinib and 21.2 [16.3–27.4] months for sunitinib [adjusted HR 0.80 [95% CI: 0.53–1.21]; \(p =\text{not reported}\)][^15] Both of the HRs above were adjusted by stratification factors [IMDC risk groups and presence or absence of bone metastases] ORR: Original analysis: cabozantinib, 33% [95% CI: 23–44%]; sunitinib, 12% [95% CI: 5.4–21%][^16] Updated analysis: cabozantinib, 20% [95% CI: 12–31%]; sunitinib, 9% [95% CI: 4–18%][^17] | 77 patients [98.7%] had at least one AE [any grade] 52 patients [66.7%] had grade 3–4 AE 16 patients [20%] discontinued treatment 36 patients [46%] had a dose reduction Most common grade 3–4 AEs were hypertension, 22 [28.2%]; diarrhea, 8 [10.3%]; PPES, 6 [7.7%]; fatigue, 9 [6.4%] |

[^10]: Under assumption of 123 events [progressions or deaths], there was 85% power to detect an HR of 0.67 for PFS, using the log-rank test and a one-sided type I error of 0.12. The required number of events [123] was reached.

[^11]: Median follow-up was 21.4 months.

[^12]: Assessed by investigator, median [95% CI] PFS was 8.3 [6.5–12.4] months for cabozantinib and 5.4 [limit not reported accurately] months for sunitinib.

[^13]: Assessed by an independent radiology review committee, median [95% CI] PFS was 8.6 [6.8–14.0] months for cabozantinib and 5.3 [3.0–8.2] months for sunitinib.

[^14]: Original analysis [median follow-up, 21.4 months]: median [95% CI] OS was 30.3 [14.6–35.0] months for cabozantinib and 21.8 [16.3–27.0] months for sunitinib.

[^15]: Updated analysis [median follow-up, 35.4 months]: median [95% CI] OS was 26.1 [14.6, upper limit not estimable] months for cabozantinib and 21.2 [16.3–27.4] months for sunitinib.

[^16]: Original analysis: cabozantinib, 33% [95% CI: 23–44%]; sunitinib, 12% [95% CI: 5.4–21%].

[^17]: Updated analysis: cabozantinib, 20% [95% CI: 12–31%]; sunitinib, 9% [95% CI: 4–18%].
| Trial name (and reference of primary publication) | Tumor type and patient population | Line of therapy or patient treatment history | Treatment comparison and doses | Details of statistical power | Findings for primary endpoint(s) | Findings for secondary endpoint(s) | Safety data for cabozantinib arm |
|-----------------------------------------------|----------------------------------|---------------------------------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|---------------------------------|
| EXAM12                                       | mMTCC Adult patients with unresectable locally advanced or inoperable MTC | No limit on number of prior therapies, including MKIs | Cabozantinib (n=219) versus placebo (n=111) 140 mg QD | For the OS analysis, there was 80% power to detect an HR of 0.667, using the log-rank test and a two-sided significance level of 0.04 (across interim and final analyses) | PFS: Median PFS was 11.2 months for cabozantinib and 4.0 months for placebo. Adjusted HR was 0.28 [95% CI: 0.19–0.40; \( p < 0.0001 \)]; analyses were stratified by randomization stratification factors (age and prior MKI treatment) | OS: In the analysis of OS (44% of the 217 required events), there was no significant difference between cabozantinib and placebo14 In the final analysis (minimum follow-up, 42 months), median OS was 26.6 months for cabozantinib and 21.1 months for placebo. The comparison between treatment arms was only statistically significant in the patients with RET M918T [HR, 0.60 [95% CI: 0.38–0.94; \( p = 0.03 \)] ORR was 28% in those receiving cabozantinib12 | 22% of patients discontinued treatment 82% of patients had a dose reduction Most common grade 3–4 AEs were diarrhea, 46 [21.5%]; PPES, 27 [12.6%]; hypocalcemia, 23 [10.7%]; fatigue, 21 [9.8%]; decreased weight, 21 [9.8%] |
| CELESTIAL14                                   | aHCC Patients were \( \geq 18 \) years of age and had received a pathological diagnosis of HCC that was not amenable to curative treatment | Patients had received previous treatment with sorafenib and had experienced disease progression after at least one systemic treatment for HCC. They may have up to two previous systemic treatments | Cabozantinib (n=470) versus placebo (n=237) 60 mg orally QD | Under assumption of 621 deaths in a sample size of 760, there was 90% power to detect an HR of 0.76 [cabozantinib versus placebo], using the log-rank test and a two-sided significance level of 0.05. Observed number of deaths was 484 at time of second interim analysis | PFS: Under assumption of 621 deaths in a sample size of 760, there was 90% power to detect an HR of 0.76 [cabozantinib versus placebo], using the log-rank test and a two-sided significance level of 0.05. Observed number of deaths was 484 at time of second interim analysis | OS: Median [95% CI] OS was 10.2 [9.1–12.0] months for cabozantinib and 8.0 [6.8–9.4] months for placebo. Unadjusted HR was 0.44 [95% CI: 0.36–0.52; \( p < 0.001 \)] ORR was 4% [4 PRs] for cabozantinib and 0.4% for placebo [\( p = 0.009 \)] Median TTP was 5.4 for cabozantinib and 1.9 for placebo13 HR for TTP was 0.41 [95% CI: 0.34–0.49]12 | 46% patients [9%] had at least one AE14 316 patients [68%] had grade 3–4 AEs 76 patients [16%] discontinued treatment due to cabozantinib-related AEs 291 patients [62%] had a dose reduction Most common grade 3–4 AEs were PPES, 79 [17%]; hypertension, 74 [16%]; increase in AST, 55 [12%]; fatigue, 49 [10%]; diarrhea, 46 [10%]; asthenia, 32 [7%]; increase in ALT, 23 [5%] Patients who had any-grade PPES had greater OS and PFS than those who did not have any-grade PPES [Median OS, 14.4 versus 8.4 months; median PFS, 6.5 versus 3.7; \( p \) values not reported]13 Patients who had grade 3 or above hypertension had greater OS and PFS than those who did not have grade 3 or above hypertension [Median OS, 16.1 versus 9.5 months; median PFS, 7.4 versus 4.4; \( p \) values not reported]13 |

Table 2. (Continued)
## Table 2. (Continued)

| Trial name (and reference of primary publication) | Tumor type and patient population | Line of therapy or patient treatment history | Treatment comparison and doses | Details of statistical power | Findings for primary endpoint(s) | Findings for secondary endpoint(s) | Safety data for cabozantinib arm |
|--------------------------------------------------|-----------------------------------|---------------------------------------------|-------------------------------|-----------------------------|--------------------------------|----------------------------------|---------------------------------|
| COMET-1<sup>1</sup>                              | mCRPC                              | Patients were ≥18 years of age with mCRPC and had bone metastases and disease progression after docetaxel and abiraterone acetate and/or enzalutamide | Cabozantinib (n = 682) versus prednisone (n = 346) | Under assumption of 578 deaths, there was 90% power to detect an HR of 0.75, using a log-rank two-sided test at an overall type I error level of 0.05. Observed number of deaths was 614 | OS: Median [95% CI] OS was 11.0 [10.1–11.6] months for cabozantinib and 9.8 [9.0–11.5] months for prednisone. Unadjusted HR was 0.90 (95% CI: 0.76–1.06; p = 0.213). Follow-up was up to 24 months. | PFS: Median [95% CI] PFS was 5.6 [5.5–5.6] months for cabozantinib and 2.8 [2.8–2.9] months for prednisone. Unadjusted HR was 0.48 [95% CI: 0.40–0.57; p < 0.001]. See COMET-2 row for findings on a pooled analysis of COMET-1 and COMET-2. | 228 patients (33%) discontinued treatment. 67% of patients had a dose reduction. 680 patients (100%) had at least one AE. 481 patients (71%) had grade 3–4 AEs. Most common grade 3–4 AEs were hypertension, 135 (20%); fatigue, 119 (17%); anemia, 108 (16%); asthenia, 84 (12%); decreased appetite, 55 (8.1%). |
| COMET-2<sup>2,3</sup>                            | mCRPC                              | Patients must have received three or more cycles of docetaxel or progressed after docetaxel-containing therapy and discontinued abiraterone or enzalutamide owing to disease progression | Cabozantinib (n = 61) versus MP (n = 58) | With the planned sample size of 246, there was ≥90% power for the primary endpoint of pain reduction and 80% power for OS using a two-sided chi-squared test with a significance level of 0.05. | Primary endpoint was pain response – not presented here. | OS: Median OS was 9.0 months for cabozantinib and 7.9 months for MP [stratified HR [95% CI], 0.70 [0.44–1.10]; p = 0.1]. In a combined analysis of COMET-1 and COMET-2, adjusted HR for cabozantinib versus prednisone or MP was 0.79 (95% CI: 0.67–0.95; p = 0.0012); adjusted for baseline prognostic factors [further details not reported]<sup>16</sup>. Follow-up was up to approximately 28 months. | 60 patients (100%) had at least one AE. 42 patients (70%) had grade 3–4 AEs. 10 patients (17%) discontinued treatment. 52 patients (87%) had a dose reduction. Most common grade 3–4 AEs were anemia, 13 (22%); hypertension, 13 (22%); fatigue, 11 (18%); increase in AST, 6 (10%). |

AE, adverse event; aHCC, advanced hepatocellular carcinoma; ALT, alanine aminotransferase; aRCC, advanced renal cell carcinoma; AST, aspartate aminotransferase; BID, twice daily; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; mCRPC, metastatic castration-resistant prostate cancer; MKI, multikinase inhibitor; mMTC, metastatic medullary thyroid cancer; MP, mitoxantrone plus prednisone; mRCC, metastatic renal cell carcinoma; MTC, medullary thyroid cancer; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PPES, palmar–plantar erythrodysesthesia syndrome; PR, partial response; Q3W, once every 3 weeks; QD, once daily; SD, stable disease; TKI, tyrosine kinase inhibitor; TTP, time to progression; VEGFR, vascular endothelial growth factor receptor.
Figure 3. (continued)
two previous systemic treatments. The primary endpoint was median (95% CI) OS (with 90% power to detect an HR of 0.76), which was significantly greater with cabozantinib than with placebo [10.2 (9.1–12.0) months versus 8.0 (6.8–9.4) months; HR 0.76; 95% CI: 0.63–0.92; \( p = 0.005 \)].

An analysis of patients in CELESTIAL who had received prior transarterial chemoembolization (TACE) showed that cabozantinib improved outcomes versus placebo, irrespective of prior TACE. Median OS was 11.4 months with cabozantinib versus 8.6 months with placebo for patients with prior TACE and 9.5 months versus 7.2 months for patients with no prior TACE. Characteristics and key findings from the CELESTIAL study are presented in Table 2.

**Evidence from real-world studies:** Two European real-world studies of cabozantinib in HCC were identified, the findings of which were consistent with data reported from the pivotal CELESTIAL trial (Figure 4).61,62 Both real-world studies evaluated cabozantinib as a second or later line of therapy, with median OS ranging from 7.7 to 12.9 months.62 In the first study, conducted in Austria and Germany, four patients (5%) achieved PR.61 The second study, conducted in Italy, reported a median (95% CI) PFS of 5.1 (2.7–7.5) months and DCR of 59%.62

**Evidence from nonrandomized phase I and II clinical studies:** One phase II study evaluated cabozantinib in 41 patients with HCC, most (78%) of whom had 1–2 lines of systemic therapy.

---

**Figure 3.** Comparison of outcomes for key trials of cabozantinib in patients with RCC: (a) OS, (b) PFS, (c) ORR, and (d) DCR.

Solid bars = cabozantinib; open bars = comparator (everolimus in METEOR11,20,23 and Santini et al.45; sunitinib in CABOSUN27,28; nivolumab in Stukalin et al.43); black = randomized controlled trial; gray = real-world study. N numbers are presented for the evaluable patients when available, and for the whole cohort if the number of evaluable patients has not been published.

60 mg dose.

Colomba et al.41 and Alves Costa Silva et al.42 are reports from the same study at different time points.

DCR, disease control rate; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RCC, renal cell carcinoma.
Previously. At the end of a 12-week lead-in phase of an RDT, patients receiving cabozantinib 100 mg QD had an ORR (measured by Response Evaluation Criteria in Solid Tumors version 1.0) of 5%, and the DCR was 66% overall.63

Medullary thyroid cancer. Evidence from randomized studies: One phase III RCT (EXAM study) compared cabozantinib (140 mg as capsules; \( n = 219 \)) with placebo (\( n = 111 \)) in patients with MTC, with no limit on the number of prior therapies. The study met the primary endpoint (PFS) with an HR (95% CI) of 0.28 (0.19–0.40); there was 80% power to detect an HR of 0.667. There was also a longer median OS with cabozantinib than with placebo (26.6 months versus 21.1 months). Further characteristics and key findings of the EXAM study12,31,64–67 are presented in Table 2.

Evidence from real-world studies/nonrandomized phase I and II clinical studies: No real-world studies or phase I or II studies of cabozantinib monotherapy in MTC were identified.

Figure 4. Comparison of outcomes for key trials of cabozantinib in patients with HCC: (a) OS, (b) PFS, (c) ORR, and (d) DCR. Solid bars = cabozantinib; open bars = comparator (placebo for CELESTIAL); black = randomized controlled trial; gray = real-world study. \( N \) numbers are presented for the evaluable patients when available, and for the whole cohort if the number of evaluable patients has not been published.

DCR, disease control rate; HCC, hepatocellular carcinoma; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
Differentiated thyroid cancer. Evidence from randomized studies/real-world studies: No randomized or real-world studies of cabozantinib monotherapy in DTC were identified. The results of the phase III COSMIC-311 trial of cabozantinib in patients with radioiodine-refractory DTC previously treated with BEGFR-targeted therapy were published after the searches for this review had been conducted. For completeness, the key efficacy results of COSMIC-311 are included in the Discussion.9

Evidence from nonrandomized phase I and II clinical studies: Three phase I or II studies were identified for the evaluation of patients with DTC. In one phase II study, in the first-line setting, patients receiving cabozantinib 60 mg QD had a PR rate of 54% (19/35 patients).68 Cabanillas et al.69,70 conducted a phase I study (n = 15) with cabozantinib 140 mg and a phase II study (n = 25) with cabozantinib 60 mg. The phase I study measured response in patients who were refractory to standard therapy with radioactive iodine (RAI). The numbers of patients with PR and SD were 8 (53%) and 6 (40%), respectively, out of a total of 15 patients.69 In the phase II study of patients who received up to two lines of prior VEGFR-targeted therapy, ORR (primary endpoint) was 40% and median (95% CI) OS was 34.7 (18.3–upper limit NR) months.70

Castration-resistant prostate cancer. Evidence from randomized studies: The COMET-1 and COMET-2 trials were phase III RCTs that compared cabozantinib 60 mg with prednisone, and cabozantinib 60 mg with mitoxantrone plus prednisone (MP), respectively. The study samples included men with mCRPC, more than 90% of whom had received three or more prior cancer therapies.17,34,71 COMET-1 did not meet its primary endpoint (OS); there was no significant difference between cabozantinib (n = 682) and prednisone (n = 346; the study had 90% power to detect an HR of 0.75). However, there were favorable results for cabozantinib in terms of the secondary endpoint, PFS (Table 2).17 COMET-2 had a primary endpoint of pain response, which was not significantly different for cabozantinib versus MP (15% versus 17%; p = 0.8) and is outside the scope of this SLR. In terms of additional endpoints, patients receiving cabozantinib (n = 61) demonstrated longer OS than those receiving MP (n = 58; 9.0 months versus 7.9 months; p = 0.1).16 Characteristics and key findings of these studies are presented in Table 2. In a phase II RDT, the primary endpoints were ORR during the 12-week lead-in stage and PFS after randomization.72 Patients had received no more than one prior standard chemotherapy regimen, completed at least 4 weeks prior to study entry, and received cabozantinib 100 mg QD or placebo during the trial. At the end of the 12-week lead-in phase, during which all 171 patients received cabozantinib, numbers of patients with PR, SD, and PD were 9 (5%), 127 (75%), and 18 (11%), respectively. After randomization of 31 patients, median (95% CI) PFS was 23.9 (10.7–62.4) weeks in the cabozantinib arm (n = 14) and 5.9 (5.4–6.6) weeks in the placebo arm (n = 17). HR for cabozantinib versus placebo was 0.12 (p < 0.001).

Evidence from real-world studies: No real-world studies of cabozantinib monotherapy in CRPC were identified.

Evidence from nonrandomized phase I and II clinical studies: Two phase II studies evaluated patients with mCRPC. One included 144 patients who had received at least one previous docetaxel-containing regimen and no more than three previous chemotherapy regimens. The primary endpoint was bone scan response (not reported here), and further endpoints included OS. Median (95% CI) OS was 12.1 (9.4–14.3) months in the cabozantinib 100 mg cohort (n = 93) and 9.1 (8.0–12.9) months in the cabozantinib 40 mg cohort (n = 51).73 In another study in patients with progressive CRPC and bone metastases who were naive to chemotherapy, 17/22 patients (77%) receiving cabozantinib 60 mg QD had PFS at 12 weeks (primary endpoint; see Supplemental Resource 2 for details of statistical power).74

Other tumor types. Evidence from randomized studies: An RDT studied cabozantinib 100 mg QD in 526 patients with nine different tumor types, including CRPC, gastric/gastroesophageal junction adenocarcinoma, HCC, metastatic breast cancer, melanoma, NSCLC, small-cell lung cancer, ovarian cancer and pancreatic adenocarcinoma. Primary endpoints were ORR in the 12-week lead-in phase and PFS after randomization. Overall, ORR and median PFS were 0–22% and 2.4–6.9 months, respectively.75 In a subgroup analysis of only patients with melanoma (n = 77), 66% of whom had at least one line of prior systemic therapy, ORR was 5% and median (95% CI) PFS was 4.1 (1.8–upper limit NR) months. The HR for PFS (cabozantinib versus placebo)
was 0.59 and was not statistically significant ($p=0.284$). In another subgroup analysis of patients with ovarian cancer ($n=70$) who had no more than three prior standard chemotherapy regimens, ORR (95% CI) was 21% (13–32%). After randomization, median PFS was 5.9 months in the cabozantinib arm and 1.4 months in the placebo arm (statistical significance not reported). A randomized phase II trial compared cabozantinib with chemotherapy (temozolomide or dacarbazine) in 46 patients with metastatic uveal melanoma. The primary endpoint was to evaluate whether cabozantinib could improve PFS at 4 months (PFS4) from 15% (previously described for temozolomide) to 40% with cabozantinib. PFS4 was not found to differ between the two groups, at 32% with cabozantinib and 27% with chemotherapy. Furthermore, there were no significant differences in PFS or OS for cabozantinib versus chemotherapy (median PFS: 60 days versus 59 days; median OS: 6.4 months versus 7.3 months).

**Evidence from real-world studies:** No real-world studies of cabozantinib monotherapy in other tumor types were identified.

**Evidence from nonrandomized phase I and II clinical studies:** In all, 18 phase II studies and one phase I study evaluated patients with various types of tumors. In all but one of these studies, the cabozantinib dose was 60 mg. In one study in 50 patients with relapsed or refractory metastatic urothelial carcinoma (mUC), the primary endpoint, ORR (95% CI), was 19% (9–34%). Median (95% CI) OS and PFS were 8.1 (5.2–10.3) months and 3.7 (3–6) months, respectively. Another study evaluated 36 patients with breast cancer with brain metastases, with a median of three prior lines of therapy for metastatic disease. After treatment with cabozantinib 60 mg, the primary endpoint (central nervous system ORR) was 5% in cohort 1 [human epidermal growth factor receptor 2 (HER2)+], 14% in cohort 2 (hormone receptor+ HER2−), and 0% in cohort 3 (triple negative). In a study of metastatic triple-negative breast cancer only ($n=35$), the primary endpoint, ORR (95% CI), was 9% (2–26%) in patients with up to three prior chemotherapy regimens. In a study of 52 patients with hormone-receptor-positive breast cancer with breast metastases (who had received at least one prior line of hormonal therapy or chemotherapy for metastatic disease), cabozantinib had an initial dosage of 100 mg QD, but this was reduced to 60 mg QD after the first seven patients. The bone scan response rate (primary endpoint) was 38%; 26 patients (50%) had SD as measured by Response Evaluation Criteria in Solid Tumors. Median (90% CI) OS and PFS were 19.6 (18.0–26.8) months and 4.3 (2.8–5.5) months, respectively. In one study of treatment of metastatic collecting-duct carcinoma in the first-line setting, response (primary endpoint) was partial in 2/9 patients (22%), and there were SD and PD in 2/9 patients (22%) and 3/9 patients (33%), respectively. Two studies assessed patients with any number of prior therapies. The first study included patients with grade 1/2 carcinoid ($n=41$) or pancreatic neuroendocrine tumors ($n=20$), and reported an ORR (95% CI; primary endpoint) of 15% (7–28%) and 15% (5–36%), respectively. The second study included patients with RET-rearranged lung cancers ($n=26$) and reported an ORR (95% CI) of 28% (12–49%). One study, which also measured response as the primary endpoint, evaluated patients with unresectable metastatic pheochromocytomas and paragangliomas; results showed that 6/15 patients (40%) had PR. PFS was the primary endpoint in four studies that evaluated patients with recurrent/metastatic endometrial cancer ($n=102$), cholangiocarcinoma ($n=19$), uterine carcinosarcoma ($n=15$), and gastrointestinal stromal tumor ($n=50$). Prior to the studies, patients had progressed after one or two lines of therapy. One study, in 44 patients with metastatic colorectal cancer, had 12-week PFS rate as the primary endpoint, which was 34%.

A retrospective analysis of phase II data measured OS in 108 patients with recurrent glioblastoma, in whom antiangiogenic therapy had not previously failed. After treatment with cabozantinib 100 mg or 140 mg QD, median OS was 11.0 months.

A phase II study evaluated patients with advanced Ewing sarcomas and osteosarcomas, many of whom had received two or more prior lines of therapy (Ewing sarcomas: 67%; osteosarcomas: 40%). In patients with osteosarcoma ($n=45$), ORR was 12%, with median (95% CI) PFS of 6.7 (5.4–7.9) months. In patients with Ewing sarcoma ($n=45$), ORR was 26%, with median (95% CI) PFS of 4.4 (3.7–5.6) months.

A small phase II study in eight patients with advanced Merkel cell carcinoma was closed...
prematurely, partly due to lack of response (best response was SD in one patient). Next-generation sequencing did not detect any genetic alteration in either MET or VEGFR2. Another phase II study, in 25 patients with salivary gland cancer, reported ORRs of 6% for those with adenoid cystic carcinoma, 20% for those with salivary duct carcinoma, and 0% for those with other salivary gland cancers; median (95% CI) PFS was 12.6 (6.8–18.4) months, 9.0 months (insufficient events for 95% CI) and 6.9 (0–15.2) months, respectively. Finally, a phase I study of cabozantinib in patients with advanced or metastatic solid tumors included an expansion cohort of patients with NSCLC (cabozantinib was dosed at 60 mg in the expansion cohort). Objective responses were seen in 4/23 patients (17%) in the dose-escalation cohorts and 4/20 patients (20%) in the NSCLC expansion cohort.

Safety of cabozantinib monotherapy

Renal cell carcinoma. Evidence from randomized studies: In two RCTs, the proportion of patients who experienced grade 3–4 adverse events (AEs) was 67–68%; the most common grade 3–4 AEs with cabozantinib 60 mg treatment were hypertension (15–28%), diarrhea (10–11%), fatigue (6–9%), and palmar–plantar erythrodysesthesia syndrome (PPES; 8%). Overall, 9–20% of patients discontinued treatment owing to AEs and 46–60% required a dose reduction. All safety findings of the METEOR trial and the CABOSUN trial are presented in Table 2.

Evidence from real-world studies: In all, 11 real-world studies that reported safety data relating to cabozantinib in patients with RCC were identified. Six studies reported the overall proportions of patients with grade 3–4 AEs, ranging from 15% to 49% of patients, which were lower than those reported in RCTs. Four real-world studies reported the most common grade 3–4 AEs: hypertension (4–7%), diarrhea (3–10%), fatigue (2–23%), and PPES (or hand–foot skin reaction; 2–12%) that were all seen at broadly similar levels to those reported in RCTs. Other grade 3–4 AEs reported in the real-world studies in more than 2% of patients in at least one study were as follows: deep venous thrombosis or pulmonary embolism (4–13%); asthenia (7%); proteinuria (including nephrotic range; 1–7%); mucosal inflammation or mucositis (3–5%); increased aspartate aminotransferase (AST), alanine aminotransferase (ALT) or transaminis (1–5%); rash (4%); anemia (0–3%); and pneumonitis (1–2%). Nine studies reported the proportions of patients who discontinued treatment owing to AEs, which ranged from 4% to 16% (insufficient events for 95% CI) and were broadly similar to those reported in RCTs. The proportions of patients who required dose reductions owing to AEs were reported in nine studies, which ranged from 23% to 69% and were consistent with those seen in the RCTs.

In a retrospective analysis (n = 65), results showed that the rate of AEs was greater in patients who received a reduced starting dose of cabozantinib than in those who received a starting dose of 60 mg (95% versus 66%). Another study observed a rate of dose reductions of 57% in 21 patients receiving cabozantinib 60 mg.

A European real-world study of 337 patients with advanced RCC (CASSIOPE) found that AE-related dose modifications were similar for patients initiating cabozantinib at the recommended 60 mg and for those initiating at any dose (dose reductions in 46% versus 39%; discontinuations in 11% versus 10%).

In two analyses (n = 91–96) of Italian real-world data for treatment beyond the first-line setting, rate of grade 3–4 AEs after treatment with cabozantinib 60 mg was 21–36% (most common AEs were asthenia and diarrhea), and rate of dose reduction was 42%.

In a UK study (n = 128), the most common grade 3–4 AEs following treatment with cabozantinib (dose not reported) were fatigue (11%) and diarrhea (9%), and 55% of patients required a dose reduction. In a North American observational study, 86 patients with metastatic clear-cell RCC received cabozantinib following progression while undergoing ICIB; dose reductions for AEs occurred in 45% of patients [most commonly fatigue (27%) and PPES (16%)].

Fatigue was also the most common AE (52%) in a study of patients with non-clear-cell RCC; the most common grade 3 AEs were skin toxicity (including PPES: 4%), hypertension (4%), and diarrhea (3%).
In a Polish real-world retrospective analysis of 115 patients with metastatic RCC who had received prior VEGF-targeted therapy, the most common grade 3–4 AEs with cabozantinib 60 mg were fatigue (23%), PPES (12%), and diarrhea (10%). Only 4% of patients discontinued treatment owing to AEs. An evaluation of cabozantinib in 91 patients with metastatic RCC in a real-world setting in France reported that 35% of patients had more than 10% weight loss and that 11% experienced more than 20% weight loss. Fatigue was the most common AE (80%) in a US retrospective chart review of 35 patients with metastatic RCC, followed by gastrointestinal AEs (54%), PPES (26%), and hypertension (23%). Four patients (12%) discontinued owing to AEs.

**Evidence from nonrandomized phase I and II clinical studies:** In a phase I study of 25 patients with clear-cell RCC with refractory tumors or tumors that progressed following standard therapies, the most common grade 3 AEs were hypophosphatemia [n = 10 (40%)], fatigue [n = 5 (20%)], and hyponatremia [n = 5 (20%)] after treatment with cabozantinib 140 mg QD. There were three reports of grade 4 AEs, including pulmonary embolism, peritoneal hemorrhage, and a mental status change (not related to cabozantinib). A phase II, open-label, single-arm study of cabozantinib (60 mg QD) in Japanese patients (n = 35) with advanced RCC who had received at least one prior TKI reported a safety profile consistent with those reported in other studies. Hypertension was the most common AE of grade 3 or above (11%), followed by PPES, diarrhea, proteinuria, abnormal hepatic function, decrease appetite, and fatigue (all 9%). Two patients (6%) discontinued owing to AEs.

**Hepatocellular carcinoma. Evidence from randomized studies:** The phase III CELESTIAL trial of cabozantinib (tablets, 60 mg) in patients with advanced HCC following prior sorafenib therapy reported grade 3–4 AEs in 68% of the safety population (n = 467). The most common grade 3–4 AEs were PPES (17%), hypertension (16%), increased ALT (12%), fatigue (10%), and diarrhea (10%). In a retrospective analysis of the AEs observed in the CELESTIAL trial, results showed that the development of any grade PPES or hypertension of grade 3 or above was associated with prolonged OS and PFS. A retrospective analysis showed that cabozantinib may have a manageable safety profile in patients in CELESTIAL who had deterioration of liver function to Child–Pugh B by study week 8. In the Child–Pugh B subgroup, versus the overall population, there were similar rates of dose reductions (61% versus 62%) and discontinuations due to AEs (18% versus 16%). Rates of grade 3–4 PPES (17% versus 8%) and hypertension (16% versus 8%) were higher in the Child–Pugh B subgroup than in the overall population. Further safety findings from the CELESTIAL study are presented in Table 2.

**Evidence from nonrandomized phase I and II clinical studies:** In a phase II study (n = 41), the most common AEs of grade 3 or above following cabozantinib 100 mg QD were diarrhea (20%), PPES (termed as hand-foot syndrome; 15%), thrombocytopenia (15%), hypertension (10%), and increased AST (10%).

**Medullary thyroid cancer. Evidence from randomized studies:** One RCT (cabozantinib arm, n = 219) identified diarrhea PPES and fatigue as the most common grade 3–4 AEs with cabozantinib (capsule, 140 mg). Further safety findings from the EXAM study are presented in Table 2.

**Evidence from real-world studies/nonrandomized phase I and II clinical studies:** No real-world studies or phase I or II studies of cabozantinib monotherapy in MTC were identified.

**Differentiated thyroid cancer. Evidence from randomized studies/real-world studies:** No randomized studies or real-world studies of cabozantinib monotherapy in DTC were identified. As noted earlier, the literature searches for this review were conducted before the results of the COSMIC-311
Evidence from nonrandomized phase I and II clinical studies: In a phase I study \((n=15)\) by Cabanillas et al.,\(^{69}\) rates of discontinuation and dose reduction were 7% and 93%, respectively, with cabozantinib 140 mg. In a subsequent phase II study \((n=25)\),\(^{70}\) the rate of dose reduction was 56% following a starting dose of 60 mg. With cabozantinib 140 mg, the most common AEs (grade 3 or above) were hyponatremia (27%), and diarrhea and increased lipase (both 20%). With cabozantinib 60 mg, the most common AEs (grade 3) were hypophosphatemia (16%), and fatigue, weight loss, lipase or amylase elevation, and neutropenia (all 12%).

Another phase II study \((n=35)\), in the first-line setting, found that the most common treatment-related AEs were hyperglycemia, diarrhea, fatigue/malaise, and weight loss, following treatment with cabozantinib 60 mg.\(^{68}\)

Castration-resistant prostate cancer: Evidence from randomized studies: In two RCTs that evaluated 61 and 682 patients treated with cabozantinib 60 mg, the most common grade 3–4 AEs were found to be hypertension and fatigue. Further safety findings of COMET-1\(^{17}\) and COMET-2\(^{16,71}\) are presented in Table 2.

In a phase II RDT that evaluated 171 patients with mCRPC who received cabozantinib 100 mg and one or no prior standard chemotherapy regimens, fatigue \([n=27 (16\%)]\) and hypertension \([n=21 (12\%)]\) were the most common grade 3 AEs. The rate of discontinuation during the lead-in stage was 12%.\(^{72}\)

Evidence from real-world studies: No real-world studies of cabozantinib monotherapy in other tumor types were identified.

Evidence from nonrandomized phase I and II clinical studies: Three phase II studies \((n=19, 51, \text{and } 144)\) examined AEs in patients with mCRPC receiving cabozantinib. Common AEs (grade 3 or above) were fatigue (14%)\(^{73}\) and hypertension (13%)\(^{102}\) in those receiving 40 mg; venous thromboembolism (23%) and diarrhea (14%)\(^{74}\) in those receiving 60 mg; and fatigue (27%) in those receiving 100 mg.\(^{73}\) One study reported the rate of discontinuation, which was 25% in the 100 mg cohort and 18% in the 40 mg cohort.\(^{73}\)

Other tumor types. Evidence from randomized studies: In an RDT of cabozantinib 100 mg QD of various tumor types, the rates of dose reduction were 74% (390/526 patients) overall,\(^{75}\) 29% in metastatic melanoma (22/77 patients),\(^{76}\) and 37% in ovarian cancer (26/70).\(^{77}\) Fatigue and diarrhea were among the most common grade 3–4 AEs. In a randomized phase II trial of cabozantinib in patients with mUC, grade 3–4 AEs were thromboembolic events (13%) and hypertension (20%).\(^{78}\)

Evidence from real-world studies: No real-world studies of cabozantinib monotherapy in other tumor types were identified.

Evidence from nonrandomized phase I and II clinical studies: In all, 16 phase II studies evaluated the safety of cabozantinib 60 mg in various tumor types.\(^{80,83,85–95,103}\) The rate of dose reductions ranged from 34%\(^{82}\) to 87%\(^{87}\) in seven studies that reported these data. The most common grade 3–4 AEs included hypertension (\(\leq 36\%\) in 10 studies),\(^{80,83,85,86,88,90,91,95}\) diarrhea (\(\leq 26\%\) in seven studies),\(^{80,81,83,85,90,91,95}\) and increased lipase (\(\leq 15\%\) in five studies).\(^{81,82,86,91,93}\)

In a phase I study of patients with advanced or metastatic solid tumors, including an expansion cohort of patients with NSCLC, the most common grade 3–4 AEs were gamma glutamyl transferase increase (17%), hypertension (13%), and lymphopenia (13%) in the dose-escalation cohort, and hypertension (30%), neutropenia (25%), and ALT increase, PPES, hypophosphatemia, and dyspnea (all 15%) in the NSCLC expansion cohort. The recommended phase II dose for cabozantinib was 60 mg.\(^{96}\)

Biomarkers for response to cabozantinib. Of 114 articles identified from the SLR, 54 report findings related to biomarkers. The biomarkers identified include RET mutational status (seven studies),\(^{12,64–67,101,104}\) presence of bone metastases (five studies),\(^{28,40,66,105,106}\) MET expression level (five studies),\(^{18,19,29,107,108}\) RAS mutational status (four studies),\(^{67,92,101,104}\) circulating tumor cells (two studies),\(^{73,102}\) and alpha-fetoprotein (three studies).\(^{109–111}\) Six studies investigated tumor characteristics, including diameter and volume.\(^{97,112–115}\) The remaining studies included...
Various biomarkers, such as plasma and cell biomarkers, was the most commonly investigated biomarker; all seven studies were subgroup analyses of MTC study populations. Patients with positive RET-mutation status (mainly RET M918T) generally experienced greater cabozantinib treatment benefit (prolonged OS and PFS with cabozantinib versus placebo) than patients without RET mutations. In a post hoc analysis of the CABOSUN trial, including 131 patients with RCC in whom MET expression was determined by immunohistochemistry, findings suggested the treatment effect (cabozantinib versus sunitinib) may be stronger in the group with MET overexpression than in the MET-negative group [HR (95% CI) for PFS: 0.32 (0.16–0.63) versus 0.67 (0.37–1.23)], respectively. In another study (n = 90), higher soluble MET (sMET) concentrations were associated with improved PFS in patients with osteosarcoma (7.8 months versus 5.4 months for the sMET < 300.6 ng/mL and ≥300.6 ng/mL groups, respectively; log-rank p = 0.0167). No association has been observed between MET expression and treatment response in patients with Ewing sarcoma, NSCLC, or urothelial carcinoma.

**Discussion**

In carrying out a thorough systematic review of the literature, we have captured a wealth of evidence from 114 articles reporting on the efficacy, effectiveness, and safety of cabozantinib as a monotherapy for the treatment of solid tumors.

The review captured key efficacy evidence from randomized trials that have supported the approval of cabozantinib for RCC (METEOR and CABOSUN trials), MTC (EXAM trial), and HCC (CELESTIAL trial). Evidence for approved indications is continuing to grow. The phase IV EXAMINER trial (NCT01896479) compared cabozantinib (60 mg tablets and 140 mg capsules) in patients with metastatic MTC. Activity in patients with advanced MTC was shown for both dose regimens, but the 60 mg tablet did not meet the pre-specified non-inferiority criteria for PFS versus the 140 mg capsule (HR 1.24; 95% CI: 0.90–1.70). The safety profile was consistent with that observed previously with cabozantinib the 60 mg tablet versus 140 mg capsules associated with a non-significant lower frequency of Grade 3 AEs (63% versus 72%), dose reductions (69% versus 81%), and discontinuations due to AEs (23% versus 36%).

As well as approved indications, we identified studies of cabozantinib in additional tumor types. Among these, CRPC was the most studied tumor type in randomized trials of cabozantinib; two RCTs (COMET-1 and COMET-2) did not provide supporting evidence for cabozantinib versus prednisone or MP, while an RDT did demonstrate the improved efficacy of cabozantinib versus placebo. Cabozantinib monotherapy in CRPC is being studied further in two ongoing phase II studies. The aim of one randomized study is to compare immediate prostatectomy versus cabozantinib followed by prostatectomy in patients with high-risk prostate cancer (NCT03964337), and the aim of the second single-arm study is to determine the effectiveness of cabozantinib in the treatment of patients with mCRPC (NCT04631744). Based on the 140 active cabozantinib monotherapy studies listed on ClinicalTrials.gov in May 2021, 27 are in indications that are not yet approved, including the recently published COSMIC 311 trial (NCT03690388; estimated study completion, December 2022). COSMIC 311 was a phase III RCT comparing cabozantinib with placebo and focuses on patients with RAI-refractory DTC who progressed during or following treatment with ≤2 prior VEGFR inhibitors. As is the case for other types of systemic therapy, there are relatively few studies of cabozantinib (and other TKIs) in DTC populations, probably because patients with DTC largely respond well to standard surgical treatment and RAI therapy. The COSMIC 311 results (published after the bibliometric searches were conducted and so not included in the quantitative analysis of the search results) reported significantly prolonged PFS with cabozantinib compared with placebo (HR 0.22, 95% CI: 0.13–0.36; p < 0.0001); the safety profile was manageable and consistent with the known safety profile of cabozantinib.

A recent review emphasized that antiangiogenic drugs, such as cabozantinib, are of particular interest in ovarian cancer, in which immunotherapy has achieved only modest results. Our SLR supports the use of antiangiogenic therapy in patients with ovarian cancer, albeit from a single study that reported prolonged PFS with cabozantinib versus placebo (significance not reported) in pretreated patients with ovarian cancer.
Additionally, a phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with incurable, refractory, germ cell tumors, including ovarian germ cell tumors, started in May 2021 (NCT04876456).

The remaining tumor types identified in this SLR, which included breast cancer and mUC, were evaluated in single-arm, phase I and II studies only; in breast cancer, ORR was 0–17%.[81,82] In mUC, ORR was 19% and median OS was 8.1 months.[80] Across a variety of tumor types, clinical evidence continues to be generated.

This SLR showed that AEs were similar across disease types and were in line with those commonly observed for other TKIs.[110] The most common AEs were hypertension, diarrhea, fatigue, lipase elevation, and PPES. Cases of hyponatremia mainly occurred with higher doses of cabozantinib (140 mg versus 60 mg).[69] AEs were managed well with dosing adjustments as part of standard practice. Even with rates of dose reduction of 46–62% in phase III RCTs (from a starting dose of 60 mg), patients experienced improved efficacy relative to everolimus, sunitinib, and placebo.[13,14,28]

Evidence of the real-world effectiveness of cancer therapies is vital, because it demonstrates whether findings observed during monitored clinical settings and among selected patient populations can be translated to clinical practice. This review captured several real-world studies of cabozantinib in Europe, North America, Asia, and Australasia for patients with RCC,[35–43,44,47] 17–33%,[13,21,28,29] 75–83%,[13,28,29] and 50–96%,[13,53–55] respectively). Likewise, in RCC, OS, PFS, ORR, and DCR were comparable between the CELESTIAL trial (10.2 months,[14] 5.2 months,[14] 4%[14] and 64%,[14] respectively) and the real-world studies (7.7–12.9 months,[58,59] 5.1 months,[62] 5%[61] and 59%,[62] respectively). In terms of safety data, the overall percentages of patients with RCC experiencing grade 3–4 AEs were lower in real-world studies (15–49%[35,44,46,47,55,99]) than in the RCTs (67–68%[13,28]). The report of the Italian Managed Access Program proposed that the lower tolerability in the real-world studies may be related to bias due to the retrospective nature of the studies, the smaller sample sizes, and the improvements in management of dose and AEs because of better comprehension of the activity of cabozantinib in the clinic.[44] For both RCC and HCC, rates of dose reductions and discontinuations were consistent with clinical trials.

Almost half of the publications included in this review (54 of the 114) reported the results of biomarker analyses. RET mutational status was the most frequently studied biomarker; all studies were in patients with MTC. Other biomarkers that featured in the eligible publications included the following: bone metastases, MET expression levels, RAS mutational status, circulating tumor cells, alpha-fetoprotein, and tumor characteristics. Detailed analysis of the biomarker evidence was beyond the scope of this review, but it is an important area of research, given the potential value of cancer biomarkers in clinical practice. Depending on the type, biomarkers could be used for determining prognosis, monitoring progression of the disease, or measuring response to treatment.[131] More prospective studies are needed to explore predictive biomarkers for tumor response to cabozantinib.

The strength of this SLR is its comprehensiveness. To our knowledge, given that there was no restriction by disease type, this is the most comprehensive review of cabozantinib monotherapy to date. Although not included in this manuscript, studies of cabozantinib used in combination with other therapies have been discussed in a separate manuscript (citation to be included once available). The main limitation of the current review is the high proportion of abstracts, in which information is often incomplete and for which peer review may have been less stringent. However, inclusion of congress materials allowed us to capture the most up-to-date findings, even if full results have not yet been published, which is important for the fast-moving field of oncology.

In conclusion, in this extensive review of the literature, the efficacy and safety of cabozantinib monotherapy has been demonstrated for the treatment of various types of solid tumor. Real-world effectiveness has been demonstrated for RCC, and initial data are encouraging for HCC,
indicating that positive findings from clinical trials do, indeed, translate into tangible benefits for patients in clinical practice. Ultimately, while evidence continues to be generated for various tumors, patient prognosis does not only rely on effective treatments, but also on patient education, consistent monitoring and early detection by healthcare providers, and the application of emerging management strategies evidenced in the literature.

Ethics approval
Not applicable.

Consent to participate
Not applicable.

Consent for publication
Not applicable.

Author contributions
Pablo Maroto: Conceptualization; Methodology; Writing – review & editing.
Camillo Porta: Methodology; Writing – review & editing.
Jaume Capdevila: Methodology; Writing – review & editing.
Andrea B. Apolo: Methodology; Writing – review & editing.
Santiago Viteri: Methodology; Writing – review & editing.
Cristina Rodriguez-Antona: Methodology; Writing – review & editing.
Lidia Martin: Methodology; Writing – original draft; Writing – review & editing.
Daniel Castellano: Conceptualization; Methodology; Writing – review & editing.

ORCID iDs
Pablo Maroto https://orcid.org/0000-0002-0030-0412
Daniel Castellano https://orcid.org/0000-0002-9106-0687

Acknowledgements
The authors thank Lisa Law and Obaro Evuarherhe of Oxford PharmaGenesis, Oxford, UK, for performing the literature review and providing medical writing support. This support was funded by Ipsen UK in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Ipsen.

Conflict of interest statement
PM is on advisory boards for Astellas, AstraZeneca, Bayer, Bristol, Ipsen, Janssen, Novartis, Pfizer, and Roche, and has received research grants from Bayer and Roche. CP has an advisory role with AstraZeneca, Bristol Myers Squibb, Eisai, EUSA Pharma, General Electric Healthcare, Ipsen, Janssen, MSD, Novartis and Pfizer; has been a speaker for Bristol Myers Squibb, EUSA Pharma, General Electric Healthcare, Ipsen, and Pfizer; and has been a protocol steering committee member for Bristol Myers Squibb, Eisai and EUSA Pharma; and has provided expert testimony for EUSA Pharma and Pfizer. JC has a scientific consultancy role (speaker and advisory roles) for Advanced Accelerator Applications, Amgen, Bayer, Eisai, Exelixis, Ipsen, ITM, Merck Serono, Novartis, Pfizer, Sanofi and Sirlex, and has received research grants from Advanced Accelerator Applications, AstraZeneca, Bayer, Eisai, Novartis, and Pfizer. ABA has no interests to declare. SV reports personal fees and nonfinancial support from Bristol Myers Squibb, personal fees and nonfinancial support from Roche, personal fees from MSD, personal fees from AbbVie, nonfinancial support from OSE PHARMA, and nonfinancial support from Merck. CR-A has no interests to declare. LM is an employee of Ipsen. DC has received institutional research funding from Janssen Oncology; has received travel and accommodation expenses from AstraZeneca (Spain), Bristol Myers Squibb, Pfizer and Roche; and has a consulting or advisory role with Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Ipsen, Janssen Oncology, MSD Oncology, Novartis, Pfizer, Pierre Fabre, Roche/Genentech, and Sanofi.

Availability of data and material
Not applicable.

Code availability
Not applicable.
Supplemental material
Supplemental material for this article is available online.

References
1. Osanto S and van der Hulle T. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. *Ther Adv Urol* 2018; 10: 109–123.

2. Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. *Oncogene* 2016; 35: 2687–2697.

3. Khan KA and Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. *Nat Rev Clin Oncol* 2018; 15: 310–324.

4. Yang J, Yan J and Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. *Front Immunol* 2018; 9: 978.

5. Atkins MB and Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. *Cancer Treat Rev* 2018; 70: 127–137.

6. Ipsen Pharma. Cabometyx (summary of product characteristics). *European Medicines Agency*. Available at: https://www.ema.europa.eu/en/documents/product-information/cabometyx-epar-product-information_en.pdf (2021, accessed 25 June 2021).

7. Ipsen Pharma. Cometriq (summary of product characteristics). *European Medicines Agency*. Available at: https://www.ema.europa.eu/en/documents/product-information/cometriq-epar-product-information_en.pdf (2021, accessed 25 June 2021).

8. European Medicines Agency. Summary of opinion (post authorisation): Cabozantinib (cabozatinib). Available at: https://www.ema.europa.eu/en/documents/smoop/chmp-post-authorisation-summary-opinion-cabozantinib-ii-23_en.pdf (accessed 26 April 2022).

9. Brose MS, Robinson B, Sherman SI, et al. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: results from the phase 3 COSMIC-311 trial. *J Clin Oncol* 2021; 39(Suppl. 15): 6001.

10. Exelixis Inc. Cabometyx (highlights of prescribing information). *Food & Drug Administration*. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s012lbl.pdf (2022, accessed 7 April 2022).

11. Exelixis Inc. Cometriq (highlights of prescribing information). *Food & Drug Administration*. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203756s009lbl.pdf (2020, accessed 25 June 2021).

12. Schlumberger M, Elisei R, Müller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. *Ann Oncol* 2017; 28: 2813–2819.

13. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* 2015; 373: 1814–1823.

14. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N Engl J Med* 2018; 379: 54–63.

15. Choueiri TK, Powles T and Burotto M. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 2021; 384: 829–841.

16. Basch EM, Scholz M, de Bono JS, et al. Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: a randomized phase 3 trial with a primary pain endpoint. *Eur Urol* 2019; 75: 929–937.

17. Smith M, De Bono J, Sternberg C, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. *J Clin Oncol* 2016; 34: 3005–3013.

18. Neal JW, Dahlberg SE, Wakelee HA, et al. A randomized phase 2 trial of cabozantinib, erlotinib or the combination as 2nd or 3rd line therapy in EGFR wild-type NSCLC: ECOG-ACRIN E1512. *J Thorac Oncol* 2015; 10(9 Suppl. 2): S373.

19. Neal JW, Dahlberg SE, Wakelee HA, et al. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. *Lancet Oncol* 2016; 17: 1661–1671.

20. National Institute for Health and Care Excellence. The social care guidance manual. Appendices B to D. Available at: https://www.nice.org.uk/process/pmg10/chapter/introduction (2019, accessed 11 November 2019).
21. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol* 2016; 17: 917–927.

22. Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. *J Clin Oncol* 2018; 36: 765–772.

23. Mainwaring P, Powles T, Escudier BJ, et al. Overall survival (OS) in meteor, a randomised phase III trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC). *Asia Pac J Clin Oncol* 2017; 13(Suppl. 4): 109.

24. Motzer RJ, Escudier B, Powles T, et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. *Br J Cancer* 2018; 118: 1176–1178.

25. Powles T, Escudier B and Mainwaring PN. METEOR: results from the randomized phase 3 trial of cabozantinib versus everolimus in pts with advanced renal cell carcinoma (RCC). *BJU Int* 2015; 116(Suppl. 5): 19.

26. Tannir NM, Powles T, Escudier B, et al. Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. *Kidney Cancer* 2020; 4: 29–39.

27. Donskov F, Motzer RJ, Voog E, et al. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. *Eur J Cancer* 2020; 126: 1–10.

28. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. *J Clin Oncol* 2017; 35: 591–597.

29. Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. *Eur J Cancer* 2018; 94: 115–125.

30. Oya M, Tamada S, Tatsugami K, et al. A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma. *J Clin Oncol* 2020; 38(15 Suppl.): 5089.

31. Schoffski P, Elisei R, Müller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. *J Clin Oncol* 2012; 30(15 Suppl.): 5508.

32. Waidmann O, Merle P, Rimassa L, et al. Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC). *Oncol Res Treat* 2018; 41(Suppl. 4): 283–284.

33. Abou-Alfa GK, Meyer T, Cheng AL, et al. Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial. *J Clin Oncol* 2019; 37(15 Suppl.): 4088.

34. Sonpavde GP, Pond GR, Fizazi K, et al. Cabozantinib for progressive metastatic castration-resistant prostate cancer following docetaxel: combined analysis of two phase 3 trials. *Eur Urol Oncol* 2020; 3: 540–543.

35. Gomez de Liano Lista A, Venugopal B, Fife K, et al. Cabozantinib in metastatic renal cell carcinoma (mRCC): data from UK expanded access program (EAP). *Ann Oncol* 2018; 29(8 Suppl.): VIII317.

36. Pillai M, Powles T, Szabados B, et al. A non-interventional retrospective study to describe early clinical experience with cabozantinib in patients with advanced renal cell carcinoma (aRCC) in the United Kingdom. *J Clin Oncol* 2020; 38(15 Suppl.): e17089.

37. Iacovelli R, Ciccarese C, Facchini G, et al. Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis. *Target Oncol* 2020; 15: 495–501.

38. Martini DJ, Shabto JM, Liu Y, et al. Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts). *J Clin Oncol* 2019; 37(7 Suppl.): 671.

39. Zhang H, Basappa NS, Joy I, et al. Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): results from the Canadian Kidney Cancer Information System (CKCis). *J Clin Oncol* 2020; 38(6 Suppl.): 682.

40. Gross-Goupil M, Flechon A, Chevreau C, et al. Real-world data of cabozantinib in patients with VEGF-refractory metastatic renal cell carcinoma (mRCC): results from the French Early Access
41. Colomba E, Alves Costa Silva C, Le Teuff G, et al. Weight loss is an underestimated adverse event with cabozantinib in patients with metastatic renal cell carcinoma (mRCC). *Ann Oncol* 2019; 30(Suppl.): v390–v391.

42. Alves Costa Silva C, Le Teuff G and Hirsch L. Improved response rate of cabozantinib after immune checkpoint therapy in patients with metastatic renal cell carcinoma. *Kidney Cancer* 2020; 4(Suppl. 1): S26–S27.

43. Stukalin I, Wells JC, Graham J, et al. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Curr Oncol* 2019; 26: e175–e179.

44. Procopio G, Prisciandaro M, Iacovelli R, et al. Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program. *Clin Genitourin Cancer* 2018; 16: e945–e951.

45. Santini D, Stellato M, De Giorgi U, et al. Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): a Meet-URG group real-world study (Meet-Uro 7). *J Clin Oncol* 2020; 38(Suppl. 5): 607s–608s.

46. Procopio G, Hamberg P, Bigot P, et al. 730P interim analysis of CASSIOPE: a real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe. *Ann Oncol* 2020; 31(Suppl. 4): S371.

47. Bodnar L, Kopczyńska A, Żołnierek J, et al. Real-world experience of cabozantinib as second- or subsequent line treatment in patients with metastatic renal cell carcinoma: data from the Polish managed access program. *Clin Genitourin Cancer* 2019; 17: e556–e564.

48. Fife K, Szabados BE, Klair B, et al. 741P clinical outcomes stratified by Charlson Comorbidities Index (CCI) score from a retrospective study of patients with advanced renal cell carcinoma (aRCC) who received cabozantinib as part of the UK Managed Access Program (MAP). *Ann Oncol* 2020; 31(Suppl. 4): S576–S577.

49. Groso-Goupil M, Fléchon A, Mourey L, et al. 722P cabozantinib in elderly patients: results from a subanalysis of the CABOREAL study. *Ann Oncol* 2020; 31(Suppl. 4): S566–S567.

50. Fléchon A, Chevreau CM, Topart D, et al. 732P cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: real-world data from the CABOREAL study. *Ann Oncol* 2020; 31(Suppl. 4): S572–S573.

51. Gan CL, Dudani S, Wells C, et al. Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): results from the International mRCC Database Consortium (IMDC). *J Clin Oncol* 2020; 38(Suppl. 6S): 639.

52. Martini DJ, Shabto JM, Liu Y, et al. Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo). *J Clin Oncol* 2019; 37(Suppl. 7): 1603–1608.

53. Martinez Chanzá N, Xie W, Asim Bilen M, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. *Lancet Oncol* 2019; 20: 581–590.

54. Campbell MT, Bilen MA, Shah AY, et al. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: a retrospective analysis. *Eur J Cancer* 2018; 104: 188–194.

55. McGregor BA, Lalani AA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. *Eur J Cancer* 2020; 135: 203–210.

56. Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. *Ann Oncol* 2014; 25: 1603–1608.

57. Tomita Y, Tatsugami K, Nakaigawa N, et al. Cabozantinib in advanced renal cell carcinoma: a phase II, open-label, single-arm study of Japanese patients. *Int J Urol* 2020; 27: 952–959.

58. Kelley RK, Ryoo BY, Merle P, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. *ESMO Open* 2020; 5: e000714.

59. El-Khoueiry A, Meyer T, Cheng A, et al. SO-9 outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo. *Ann Oncol* 2020; 31(Suppl. 3): S220.

60. Yau T, Cheng AL, Meyer T, et al. Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC). *Ann Oncol* 2018; 29(Suppl. 8): viii237–viix238.
61. Finkelmeier F, Scheiner B, Leyh C, et al. Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-world cohort. *J Clin Oncol* 2020; 38: e16668.

62. Tovoli F, Dadduzio V, De Lorenzo S, et al. 999P real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. *Ann Oncol* 2020; 31(Suppl 4): S695.

63. Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatic cellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. *Ann Oncol* 2017; 28: 528–534.

64. Cohen EE, Elisei R, Schlumberger MJ, et al. Clinical activity and pharmacokinetics (PK) of cabozantinib (XL184) in patients with progressive medullary thyroid carcinoma (MTC). *Ann Oncol* 2012; 23(Suppl 9): ix154–ix155.

65. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. *J Clin Oncol* 2013; 31: 3639–3646.

66. Shah M, Elisei R and Müller S. Clinical activity of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (PTS): subgroup analysis in the phase 3 study (exam). *Thyroid* 2012; 22(Suppl 1): oral 117.

67. Sherman SI, Clary DO, Elisei R, et al. Correlative analyses of *RET* and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. *Cancer* 2016; 122: 3856–3864.

68. Brose MS, Shenoy S, Bhat N, et al. A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting. *J Clin Oncol* 2018; 36(15 Suppl.): 6088.

69. Cabanillas ME, Brose MS, Holland J, et al. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. *Thyroid* 2014; 24: 1508–1514.

70. Cabanillas ME, de Souza JA, Geyer S, et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II International Thyroid Oncology Group trial. *J Clin Oncol* 2017; 35: 3315–3321.

71. Basch EM, Scholz MC, De Bono JS, et al. Final analysis of COMET-2: cabozantinib ( cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). *J Clin Oncol* 2015; 33(7 Suppl.): 141.

72. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. *J Clin Oncol* 2013; 31: 412–419.

73. Smith MR, Sweeney CJ, Corn PG, et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. *J Clin Oncol* 2014; 32: 3391–3399.

74. Smith DC, Daignault-Newton S, Grivap S, et al. Efficacy and effect of cabozantinib on bone metastases in treatment-naive castration-resistant prostate cancer. *Clin Genitourin Cancer* 2020; 18: 332–339.e2.

75. Schöffski P, Gordon M, Smith DC, et al. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. *Eur J Cancer* 2017; 86: 296–304.

76. Daud A, Kluger HM, Kurzrock R, et al. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. *Br J Cancer* 2017; 116: 432–440.

77. Vergote IB, Smith DC, Berger R, et al. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. *Eur J Cancer* 2017; 83: 229–236.

78. Luke JJ, Olson DJ, Allred JB, et al. Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201). *Clin Cancer Res* 2020; 26: 804–811.

79. Ellingson BM, Aftab DT, Schwab GM, et al. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. *Neuro Oncol* 2018; 20: 1411–1418.

80. Apolo AB, Nadal R, Tomita Y, et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. *Lancet Oncol* 2020; 21: 1099–1109.

81. Leone JP, Duda DG, Hu J, et al. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. *Breast Cancer Res Treat* 2020; 179: 113–123.

82. Tolaney SM, Ziehr DR, Guo H, et al. Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients. *Oncologist* 2017; 22: 25–32.
83. Xu J, Higgins MJ, Tolaney SM, et al. A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases. *Oncologist* 2020; 25: 652–660.

84. Procopio G, Ratta R, Colecchia M, et al. A phase II study of cabozantinib as first-line treatment in metastatic collecting ducts carcinoma: the BONSAI trial. *J Clin Oncol* 2019; 37(7 Suppl.): 578.

85. Chan JA, Faris JE, Murphy JE, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). *J Clin Oncol* 2017; 35(4 Suppl.): 228.

86. Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. *Lancet* 2016; 17: 1653–1660.

87. Jimenez C. A phase 2 study to evaluate the effects of cabozantinib in patients with unresectable metastatic pheochromocytomas and paragangliomas. *Endocr Pract* 2018; 24(Suppl. 1): 25.

88. Dhanı NC, Hirte HW, Burnier Jv, et al. Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): a study of the Princess Margaret, Chicago, and California phase II consortia. *J Clin Oncol* 2017; 35(15 Suppl.): 5524.

89. Goyal L, Yurgelun MB, Abrams TA, et al. A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma. *J Clin Oncol* 2015; 33(3 Suppl.): 800.

90. Mandilaras V, Dhanı NC, Tan Q, et al. Exploratory phase II evaluation of cabozantinib in recurrent/metastatic uterine carcinosarcoma (CS): a study of the Princess Margaret, Chicago, and California phase II consortia. *J Clin Oncol* 2017; 35(15 Suppl.): 5587.

91. Schöffski P, Mir O, Kasper B, et al. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and treatment of Cancer phase II trial 1317 ‘cabogist’. *Eur J Cancer* 2020; 134: 62–74.

92. Scott AJ, Cohen SJ, Basu Mallick A, et al. A phase II study investigating cabozantinib in patients with refractory metastatic colorectal cancer (AGICC 17CRC01). *J Clin Oncol* 2020; 38(4 Suppl.): 103.

93. Italiano A, Mir O, Mathoulin-Pelissier S, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2020; 21: 446–455.

94. Rabinowits G, Lezcano C, Catalano PJ, et al. Cabozantinib in patients with advanced Merkel cell carcinoma. *Oncologist* 2018; 23: 814–821.

95. van Boxtel W, Uijen M, Driessen C, et al. A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients. *J Clin Oncol* 2020; 38(15 Suppl.): 6529.

96. Nokihara H, Nishio M, Yamamoto N, et al. Phase 1 study of cabozantinib in Japanese patients with expansion cohorts in non-small-cell lung cancer. *Clin Lung Cancer* 2019; 20: e317–e328.

97. Powles TB, Escudier B, de Souza P, et al. Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial. *Ann Oncol* 2016; 27(Suppl. 6): V1284.

98. Cella D, Escudier B, Tannir NM, et al. Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial. *J Clin Oncol* 2018; 36: 757–764.

99. Procopio G, Prisciandaro M, Iacovelli R, et al. Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian expanded access program (EAP). *Ann Oncol* 2017; 28(Suppl. 5): V319–V320.

100. McElwee JH, Gourdin TS, Mikoll J, et al. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials. *J Oncol Pharm Pract* 2020; 26: 861–865.

101. Sherman SI, Elisei R and Mueller S. The impact of RET and RAS mutation status on overall survival in the EXAM trial, a phase 3 study of cabozantinib (CABO) in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC). *Thyroid* 2015; 25(Suppl. 1): A21–A22.

102. de Bono JS, Smith MR, Rathkopf D, et al. Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (MCRPC): results of a phase 2 non-randomized expansion cohort (NRE). *Ann Oncol* 2012; 23(Suppl. 9): ix296.

103. Choy E, Cote GM, Michaelson MD, et al. Abstract CT129: Phase 2 study of cabozantinib in patients with non-breast, non-prostate cancer with bone metastasis. *Cancer Res* 2017; 77(13 Suppl.): CT129.

104. Brose MS, Sherman SI, Schöffski P, et al. Correlative analyses of RET and RAS mutations
in a phase 3 study of cabozantinib in patients (PTS) with progressive, metastatic medullary thyroid cancer (MTC). Thyroid 2013; 23( Suppl. 1): A-14.

105. Konda B, Knopp MV, Martin PR, et al. Effect of cabozantinib on bone turnover markers (BTM) and bone metastases (BM) in radioiodine refractory (RAIR)-differentiated thyroid cancer (DTC). J Clin Oncol 2017; 35(15 Suppl.): e17580.

106. Martini DJ, Shabto JM, Liu Y, et al. Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo). J Clin Oncol 2019; 37(7 Suppl.): 585.

107. Powles T, Escudier B and Motzer RJ. Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC). BJU Int 2016; 118(Suppl. 5): 4.

108. Italiano A, Penel N, Toulmonde M, et al. Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French sarcoma group (FSG)/US National Cancer Institute phase II collaborative study. Ann Oncol 2018; 29( Suppl. 8): VIII753.

109. Abou-Alfa GK, El-Khoueiry AB, Meyer T, et al. Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase 3 CELlestial trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). Hepatology 2018; 68(Suppl. 1): 533A–534A.

110. Kelley RK, Rimassa L, Ryoo BY, et al. Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELlestial trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2019; 37(4 Suppl.): 423.

111. Kelley RK, Meyer T, Rimassa L, et al. Serum alpha-fetoprotein levels and clinical outcomes in the Phase III CELlestial study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2020; 26: 4795–4804.

112. Blanc JF, Meyer T, Cheng A-L, et al. Assessment of disease burden in the phase III CELlestial trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). Ann Oncol 2018; 29(Suppl. 8): VIII237.

113. Duran I, Maroto P, Suaírez C, et al. Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). J Clin Oncol 2019; 37(7 Suppl.): 550.

114. Ellingson BM, Harris RJ, Woodworth DC, et al. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials. Neuro Oncol 2017; 19: 89–98.

115. Pal SK, Motzer RJ, Fishman MN, et al. Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). J Clin Oncol 2017; 35(6 Suppl.): 522.

116. Brose MS, Elisei R and Schlumberger M. Correlative biomarker analysis in the exam trial, a phase 3 study of cabozantinib (XL184) in patients (PTS) with medullary thyroid carcinoma (MTC). Thyroid 2012; 22(Suppl. 1): A48–A49.

117. Powles T, Motzer RJ, George DJ, et al. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (RCC). Oncol Res Treat 2017; 28(Suppl. 5): v307–v308.

118. Leibowitz-Amit R, Pintilie M, Laird AD, et al. Association of changes in biomarkers with treatment with cabozantinib (cabo) in metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trial. J Clin Oncol 2015; 33(7 Suppl.): 196.

119. Martini DJ, Shabto JM, Liu Y, et al. Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo). J Clin Oncol 2019; 37(7 Suppl.): 612–612.

120. Nadal R, Parnes HL, Francis DC, et al. A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC). Ann Oncol 2016; 27(Suppl. 6): VI272.

121. Padda SK, Lara P Jr and Gettinger SN. Veri strat and epidermal growth factor receptor mutation status in a phase 1B/2 study of cabozantinib +/- erlotinib in non-small cell lung cancer. J Thorac Oncol 2015; 10(9 Suppl. 2): S291.

122. Padda SK, Rosenberg-Hasson Y and Neal JW. Correlative analysis of circulating biomarkers from a phase 1B/2 trial of cabozantinib (C) with or without erlotinib (E) in patients (pts)
with advanced or metastatic non-small cell lung cancer (NSCLC). *J Thorac Oncol* 2013; 8(Suppl. 2): S1072–S1073.

123. Flaifel A, Xie W, Braun DA, *et al.* PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN. *Clin Cancer Res* 2019; 25: 6080–6088.

124. Kline MR, Martini DJ, Liu Y, *et al.* Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C). *J Clin Oncol* 2020; 38(6 Suppl.): 734.

125. Miksad R, Cicin I, Chen Y, *et al.* Outcomes based on albumin-bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). *Ann Oncol* 2019; 30(Suppl. 4): iv134.

126. Rimassa L, Kelley RK, Meyer T, *et al.* Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC). *Ann Oncol* 2019; 30(Suppl. 5): v257–v258.

127. Yau T, Meyer T, Kelley RK, *et al.* Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC). *Ann Oncol* 2019; 30(Suppl. 9): ix48.

128. Jayarangaiah A, Sidhu G, Brown J, *et al.* Therapeutic options for advanced thyroid cancer. *Int J Clin Endocrinol Metab* 2019; 5: 26–34.

129. Borella F, Ghisoni E, Giannone G, *et al.* Immune checkpoint inhibitors in epithelial ovarian cancer: an overview on efficacy and future perspectives. *Diagnostics* 2020; 10: 146.

130. Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. *EJC Suppl* 2013; 11: 172–191.

131. Henry NL and Hayes DF. Cancer biomarkers. *Mol Oncol* 2012; 6: 140–146.